Immunovant, Inc.
IMVT
$41.82
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -32.02% | -14.41% | -21.96% | -5.19% | 38.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.02% | 40.17% | 0.05% | 13.84% | 34.94% |
| Operating Income | -26.02% | -40.17% | -0.05% | -13.84% | -34.94% |
| Income Before Tax | -28.01% | -42.35% | 1.70% | -15.47% | -37.47% |
| Income Tax Expenses | -- | -587.82% | 921.05% | 661.54% | 1,085.71% |
| Earnings from Continuing Operations | -27.04% | -38.90% | 0.44% | -15.93% | -38.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.04% | -38.90% | 0.44% | -15.93% | -38.40% |
| EBIT | -26.02% | -40.17% | -0.05% | -13.84% | -34.94% |
| EBITDA | -26.05% | -40.22% | -0.05% | -13.84% | -34.94% |
| EPS Basic | -5.61% | -13.69% | 19.41% | 2.21% | -18.32% |
| Normalized Basic EPS | -6.42% | -16.53% | 20.44% | 2.60% | -17.53% |
| EPS Diluted | -5.61% | -13.69% | 19.41% | 2.21% | -18.32% |
| Normalized Diluted EPS | -6.42% | -16.53% | 20.44% | 2.60% | -17.53% |
| Average Basic Shares Outstanding | 20.29% | 22.18% | 23.54% | 18.55% | 16.97% |
| Average Diluted Shares Outstanding | 20.29% | 22.18% | 23.54% | 18.55% | 16.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |